AMED3001 Cancer
Histopathology, Grading, Staging & Screening
Weeks 3-4 cover how cancer is diagnosed and detected. Histopathology turns a biopsy into a tissue diagnosis; grade and stage then describe how aggressive and how widespread the cancer is; biomarkers guide treatment; and population screening finds cancer before symptoms. The grade-versus-stage distinction and interpreting a pathology report are among the richest exam topics, and the Module 1 practical report (10%) is built on the cancer pathology practical. Reading a report is a data-interpretation skill examinable in the final (50%, confirm on Canvas).
What this chapter covers
- 01Tissue diagnosis: biopsy, the Haematoxylin & Eosin (H&E) stain, and reading morphology (cytology + tissue architecture)
- 02Cancer cell and nuclear features: pleomorphism, hyperchromasia, high nuclear:cytoplasmic ratio, increased and abnormal mitoses
- 03Carcinoma in situ vs invasive cancer: breach of the basement membrane
- 04GRADE = intrinsic aggressiveness (differentiation, growth pattern, mitotic count); Nottingham system for breast cancer
- 05STAGE = amount and spread, scored by TNM (Tumour, Nodes, Metastasis) → Stage I-IV
- 06Prognostic (e.g. Ki67) vs predictive (e.g. ER) biomarkers; IHC; tumour markers CEA, AFP, CA125, CA19-9
- 07Population screening: sensitivity, specificity; Australia's programs (NBCSP, BreastScreen, National Cervical Screening Program)
- 08Liquid biopsy analytes: circulating tumour cells, cfDNA/ctDNA, extracellular vesicles, tumour-educated platelets
Interpreting a breast-cancer pathology report (data interpretation)
- +1Hormone responsiveness: ER positive (90%) and PR positive (70%) means the tumour expresses hormone receptors and is hormone-responsive → a candidate for endocrine (anti-oestrogen) therapy. ER here is a PREDICTIVE biomarker.
- +1HER2 status: HER2 2+ on IHC is equivocal, and the confirmatory ISH is NOT amplified, so the tumour is not HER2-amplified/HER2-driven (it would be reported HER2-low), and HER2-targeted therapy is not indicated on this result.
- +1Stage — T: pT1c means the invasive tumour is greater than 1 cm and up to 2 cm (15 mm fits), the pathological tumour-size category.
- +1Stage — N and overall: N0 means no regional lymph-node metastasis (the sentinel node was clear). A small tumour that is node-negative is an early stage (Stage 1A on the AJCC system).
Key terms
- Histopathology
- The study of disease by microscopic examination of tissue; a biopsy stained with Haematoxylin & Eosin (H&E) lets a pathologist assess cytology and tissue architecture to make a definitive tissue diagnosis.
- Grade
- A measure of a cancer's intrinsic aggressiveness assessed microscopically from differentiation, growth pattern and mitotic count; Grade 3 is the most aggressive. Breast cancer uses the Nottingham system (tubule formation, nuclear pleomorphism, mitotic count).
- Stage (TNM)
- A measure of how much cancer is present and how far it has spread: T (tumour at the primary site), N (spread to regional lymph nodes), M (distant metastases), summarised as Stage I-IV. Survival correlates with stage.
- Carcinoma in situ vs invasive
- In situ cancer is confined within normal structures and has not breached the basement membrane; invasive cancer has breached the basement membrane into surrounding tissue.
- Prognostic vs predictive factor
- A prognostic factor correlates with outcome regardless of treatment (e.g. Ki67 proliferation index); a predictive factor correlates with response to a specific treatment (e.g. ER predicts benefit from anti-oestrogen therapy).
- Screening (sensitivity/specificity)
- Testing asymptomatic people to detect cancer early; a good screening test is sensitive (few false negatives), specific (few false positives) and cost-effective, balancing early detection against over-diagnosis.
Histopathology, Grading, Staging & Screening FAQ
What is the difference between cancer grade and cancer stage?
Grade describes how aggressive the cancer cells look under the microscope (differentiation, growth pattern, mitotic count); stage describes how much cancer there is and how far it has spread (TNM). Two tumours can share a stage but differ in grade — this contrast is one of the most reliably examined short answers.
Is ER in breast cancer prognostic or predictive?
Predictive. ER (oestrogen receptor) positivity predicts that the tumour will respond to anti-oestrogen (endocrine) therapy, so it guides treatment choice. Contrast it with Ki67, a prognostic proliferation marker that correlates with outcome.
What are Australia's national cancer-screening programs?
The National Bowel Cancer Screening Program (faecal occult blood test), BreastScreen Australia (mammography) and the National Cervical Screening Program (HPV/Pap testing). Knowing each program and its test is a common MCQ.
Can AI help me interpret a pathology report for AMED3001?
Yes — Sia can walk through a mock report line by line, explaining what ER/PR/HER2, grade and TNM each mean and how they guide treatment, and can quiz you on prognostic-versus-predictive markers. It explains the reasoning and checks yours; it does not complete your graded practical report.
Exam move
Master the grade-versus-stage distinction cold and be able to read a pathology report as a data-interpretation exercise — what ER/PR/HER2, grade and TNM tell you and how each changes management, since that skill underpins both the Module 1 practical report (10%) and exam questions. Memorise Australia's three screening programs with their tests and the prognostic-versus-predictive contrast. Ask Sia to quiz you on mock reports and screening principles; confirm the practical and exam details on Canvas.
Working through Histopathology, Grading, Staging & Screening in AMED3001? Sia is AskSia’s AI Biology tutor — ask any AMED3001 Histopathology, Grading, Staging & Screening question and get a clear, step-by-step explanation grounded in how AMED3001 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
